Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR9549 in ER+ HER2- advanced breast cancer
NCT03596658Phase 1Terminated
- Sponsor
- Hengrui
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR9549 in breast cancer, sponsored by Hengrui. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Jul 2018; status: terminated.
02
Drugs
SHR9549
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03596658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596658.